Latest

1 story

Hide weekly roundups

Tuesday, August 18

Astellas registers Phase 1/2 gene therapy trial for ASP2767 in glaucoma optic nerve damage

Trial updateASP2767 Astellas Pharma

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.